Drug Discovery News Feature: 'Can Hair Loss Be the Next GLP-1 Moment?' Surveys Peptide and Small-Molecule Pipeline
A Drug Discovery News feature surveyed the emerging hair loss treatment landscape and asked whether the category could replicate the GLP-1 obesity drug breakout. Lead candidates include Pelage Pharmaceuticals' PP405 (small-molecule topical, Phase 3 launch 2026 with FDA approval potentially 2027-2029), the MLPH peptide (preclinical, novel safe mechanism for both sexes), the APN5 peptide (Korean research team, hair growth + suppression of loss), and product launches from Ouai Haircare's $50 Bond Repair Balm and Omi Well Beauty's Hair Growth Peptides expanding the consumer category.